XML 63 R17.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Goodwill and other intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2023
Intangible assets and goodwill [abstract] |
Goodwill and other intangible assets | Goodwill and other intangible assets Movements in goodwill comprise:
(€ million) | Goodwill
Balance at January 1, 2021 | 44,364 |
Acquisitions during the period | 2,179 |
Other movements during the period(a) | (89) |
Currency translation differences | 1,602 |
Balance at December 31, 2021 | 48,056 |
Acquisitions during the period | 609 |
Other movements during the period(a) | (258) |
Currency translation differences | 1,485 |
Balance at December 31, 2022 | 49,892 |
Acquisitions during the period | 475 |
Other movements during the period(a) | (90) |
Currency translation differences | (873) |
Balance at December 31, 2023 | 49,404 |
(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, and in 2022 the loss of control of EUROAPI (see note D.2.1.). In accordance with IAS 36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma and Consumer Healthcare segments. When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note B.6.1. The allocation of goodwill by segment as of December 31, 2023 is as follows:
(€ million) | Biopharma | Consumer Healthcare |  | Total
Goodwill | 42,324 |  | 7,080 |  |  | 49,404 |
Acquisition of QRIB Intermediate Holdings, LLC (2023) The provisional purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) o f €774 million as of the acquisition d ate (September 29, 2023), a nd of goodwill provisionally measured at €475 million as of the acquisition date (see Note D.1.). Acquisition of Amunix Pharmaceuticals, Inc. (2022) The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o f €493 million as of the acquisition date (February 8, 2022), and of goodwill measured at €609 million as of the acquisition date (see Note D.2.1.). Acquisition of Translate Bio (2021) The final purchase price allocation for Translate Bio resulted in the recognition of intangible a ssets (other than goodwill) of €396 million as of the acquisition date (September 14, 2021), and of goodwill measured at €2,118 million as of the acquisition date (see Note D.2.2.). Movements in other intangible assets comprise:
(€ million) | Acquired R&D | Products, trademarks and other rights | Software | Total other intangible assets
Gross value at January 1, 2021(a) | 9,600 |  | 61,074 |  | 1,633 |  | 72,307 |
Changes in scope of consolidation(c) | 1,805 |  | 1,821 |  | — |  | 3,626 |
Acquisitions and other increases | 339 |  | 159 |  | 118 |  | 616 |
Disposals and other decreases | (313) |  | (173) |  | (16) |  | (502) |
Currency translation differences | 560 |  | 2,234 |  | 24 |  | 2,818 |
Transfers(b) | (784) |  | 791 |  | (7) |  | — |
Gross value at December 31, 2021 | 11,207 |  | 65,906 |  | 1,752 |  | 78,865 |
Changes in scope of consolidation(c) | — |  | 499 |  | (35) |  | 464 |
Acquisitions and other increases | 277 |  | 195 |  | 99 |  | 571 |
Disposals and other decreases | (72) |  | (423) |  | (48) |  | (543) |
Currency translation differences | 518 |  | 1,994 |  | 21 |  | 2,533 |
Transfers(b) | (1,576) |  | 1,408 |  | (6) |  | (174) |
Gross value at December 31, 2022 | 10,354 |  | 69,579 |  | 1,783 |  | 81,716 |
Changes in scope of consolidation(c) | 113 |  | 3,287 |  | 1 |  | 3,401 |
Acquisitions and other increases(f) | 1,062 |  | 1,970 |  | 80 |  | 3,112 |
Disposals and other decreases | (262) |  | (380) |  | (41) |  | (683) |
Currency translation differences | (242) |  | (1,584) |  | (11) |  | (1,837) |
Transfers(b) | (1,253) |  | 861 |  | (4) |  | (396) |
Gross value at December 31, 2023 | 9,772 |  | 73,733 |  | 1,808 |  | 85,313 |
Accumulated amortization & impairment at January 1, 2021(a) | (3,508) |  | (49,345) |  | (1,113) |  | (53,966) |
Amortization expense | — |  | (1,621) |  | (119) |  | (1,740) |
Impairment losses, net of reversals(d) | (150) |  | (42) |  | — |  | (192) |
Disposals and other decreases | 313 |  | 133 |  | 16 |  | 462 |
Currency translation differences | (132) |  | (1,869) |  | (21) |  | (2,022) |
Accumulated amortization & impairment at December 31, 2021 | (3,477) |  | (52,744) |  | (1,237) |  | (57,458) |
Changes in scope of consolidation(c) | — |  | — |  | 11 |  | 11 |
Amortization expense(e) | — |  | (2,099) |  | (97) |  | (2,196) |
Impairment losses, net of reversals(d) | (1,107) |  | 1,561 |  | — |  | 454 |
Disposals and other decreases | 75 |  | 411 |  | 39 |  | 525 |
Currency translation differences | (7) |  | (1,567) |  | (17) |  | (1,591) |
Transfers(b) | 388 |  | (214) |  | 5 |  | 179 |
Accumulated amortization & impairment at December 31, 2022 | (4,128) |  | (54,652) |  | (1,296) |  | (60,076) |
Changes in scope of consolidation(c) | — |  | 33 |  | — |  | 33 |
Amortization expense | — |  | (2,225) |  | (120) |  | (2,345) |
Impairment losses, net of reversals(d) | (90) |  | (842) |  | — |  | (932) |
Disposals and other decreases | 262 |  | 326 |  | 41 |  | 629 |
Currency translation differences | 94 |  | 1,184 |  | 9 |  | 1,287 |
Transfers(b) | 128 |  | 268 |  | 14 |  | 410 |
Accumulated amortization & impairment at December 31, 2023 | (3,734) |  | (55,908) |  | (1,352) |  | (60,994) |
Carrying amount at December 31, 2021 | 7,730 |  | 13,162 |  | 515 |  | 21,407 |
Carrying amount at December 31, 2022 | 6,226 |  | 14,927 |  | 487 |  | 21,640 |
Carrying amount at December 31, 2023 | 6,038 |  | 17,825 |  | 456 |  | 24,319 |
(a) Includes the impact of the IFRIC agenda decision of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form 20-F for that year). (b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets as Assets held for sale or exchange. (c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes D.1. and D.2.). (d) See Note D.5. (e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.). (f) This line mainly comprises: –the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note C.2.); –an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV’574; and –an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. “Products, trademarks and other rights” mainly comprise: •“marketed products”, with a carrying amount of €16.6 billion as of December 31, 2023 (versus €12.7 billion as of December 31, 2022 and €11.7 billion as of December 31, 2021) and a weighted average amortization period of approximately 11 years; and •“technology platforms”, with a carrying amount of €1.2 billion as of December 31, 2023 (versus €2.2 billion as of December 31, 2022 and €1.2 billion as of December 31, 2021) and a weighted average amortization period of approximately 18 years. The table below provides information about the principal “marketed products”, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:
(€ million) | Gross value | Accumulated amortization & impairment | December 31, 2023 | Amortization period (years)(a) | Residual amortization period (years)(b) | Carrying amount at December 31, 2022 | Carrying amount at December 31, 2021
Genzyme(c) | 10,279 |  | (10,071) |  | 208 |  | 10 | 2 | 621 |  | 1,032 |
Boehringer Ingelheim Consumer Healthcare(c) | 3,504 |  | (1,698) |  | 1,806 |  | 17 | 11 | 2,037 |  | 2,213 |
Aventis(c) | 33,043 |  | (33,000) |  | 43 |  | 9 | 11 | 58 |  | 73 |
Chattem(c) | 1,319 |  | (818) |  | 501 |  | 23 | 10 | 574 |  | 593 |
Protein Sciences(c) | 831 |  | (411) |  | 420 |  | 13 | 7 | 498 |  | 532 |
Ablynx(c) | 1,966 |  | (746) |  | 1,220 |  | 14 | 9 | 1,357 |  | 1,494 |
Bioverativ(c) | 8,798 |  | (3,646) |  | 5,152 |  | 14 | 9 | 4,836 |  | 3,065 |
REZUROCK | 1,907 |  | (327) |  | 1,580 |  | 12 | 10 | 1,702 |  | 1,750 |
TZIELD | 2,546 |  | (141) |  | 2,405 |  | 12 | 12 | — |  | — |
BEYFORTUS | 1,946 |  | (76) |  | 1,870 |  | 18 | 17 | 180 |  | — |
QUNOL | 741 |  | (19) |  | 722 |  | 10 | 9 | — |  | — |
Total: principal marketed products | 66,880 |  | (50,953) |  | 15,927 |  |  |  | 11,863 |  | 10,752 |
(a) Weighted averages. The amortization periods for these products vary between 1 and 25 years. (b) Weighted averages. (c) Commercialized products derived from the acquisition of these companies. The principal intangible assets brought into service during 2023 were: ALTUVIIIO (efanesoctocog alfa), which extends protection from bleeds and treats acute hemorrhages in people with hemophilia A. The asset came into service on the date of marketing approval (February 23, 2023), and has a gross value of €1,110 million. During 2022, some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ENJAYMO (sutimlimab-jome), a treatment for cold agglutinin disease. The main asset brought into service during 2021 was the Translate Bio mRNA technology platform. Amortization of other intangible assets is recognized in the income statement within the line item Amortization of intangible assets, except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. An analysis of amortization of software is shown in the table below:
(€ million) | 2023 | 2022 | 2021 |
Cost of sales | 15 |  | 10 |  | 18 |  |
Research and development expenses | 3 |  | 1 |  | 3 |  |
Selling and general expenses | 100 |  | 82 |  | 98 |  |
Other operating expenses | 2 |  | 4 |  | — |  |
Total | 120 |  | 97 |  | 119 |  |

X
- Definition The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_IntangibleAssetsAndGoodwillAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration